(aeruginascin + baeocystin + psilocybin)

all catalysts(0)

nothing on the calendar yet

News(10)

• Chutes & Ladders—Legend CEO departs without successor in place
  Legend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was elevated from CFO to CEO in 2020 after a Chinese customs investigation was opened on f…
  fiercebiotech · 2d ago
• Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
  Eli Lilly’s $3.8 billion play for AtaiBeckley has fueled speculation that Big Pharma is ready to embrace psychedelics. But while the acquisition does validate the drug class, analysts say it is unl…
  biospace · 8d ago
• Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelics
  Eli Lilly’s proposed acquisition of AtaiBeckley is “the clearest strategic validation to date” of psychedelics as an emerging pharmaceutical category, according to H.C. Wainwright. The analyst caut…
  biospace · 12d ago
• ‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics
  After Eli Lilly dived into the psychedelics space with a $2.8 billion upfront acquisition of AtaiBeckley last week, industry experts told Fierce that the deal would give the space added momentum.
  fiercebiotech · 14d ago
• Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics
  The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be embracing a long-dismissed field of research.
  biopharma_dive · 16d ago
• Lilly makes up to $3.8B psychedelics play in AtaiBeckley takeover
  With the AtaiBeckley acquisition, Eli Lilly is jumping into psychedelics, a drug class that Jefferies analysts say could herald the “biggest change” for the field of psychiatry.
  biospace · 16d ago
• J&J sees Spravato sales surge as psychedelic competitors loom
  Psychedelics, chiefly Compass Pathways' COMP360, are unlikely to make an immediate dent in the sales of Johnson & Johnson’s depression drug Spravato, H.C. Wainwright’s Patrick Trucchio told BioSpace.
  biospace · 16d ago
• Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filing
  Compass Pathways said Tuesday that patients in the second of its two pivotal psilocybin trials maintained their response to treatment for at least six months, keeping the company on track to comple…
  endpoints · 25d ago
• 10 clinical trials to watch in the second half of 2026
  The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.
  biopharma_dive · 1mo ago
• Opinion: Trump’s executive order on psychedelics is the right move. But is my field ready for it?
  The psychedelics field is getting what it has long wanted. Now it has to step up.
  stat · 2mo ago